The DOI matches its Crossref record; 85 of the 85 references it cites were found in a registry or an index.
PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee
Open accessAbstract
The recent development of immune checkpoint inhibitors (ICI) has led to promising advances in the treatment of non-small cell and small cell lung cancer patients with advanced or metastatic disease. Most of ICI target the PD-1/PD-L1 axis with the aim of restoring anti-tumor immunity. Multiple clinical trials for ICI have examined a predictive value of PD-L1 protein expression in tumor cells and/or tumor-infiltrating immune cells by immunohistochemistry (IHC), for which different assays with specific IHC platforms were applied. Of those, some PD-L1 IHC assays have been validated for the prescription of the corresponding agent for first- or second-line treatment. However, not all laboratories are equipped with the dedicated platforms and many laboratories have set up in-house or laboratory developed tests, which are more affordable than generally expensive clinical trial-validated assays. Although PD-L1 IHC test is now deployed in the most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging due to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided. As many articles have been published since the issue of the IASLC Atlas of PD-L1 immunohistochemistry testing in lung cancer, this review by the IASLC pathology committee provides updates on the indications of ICI for lung cancer in 2019, and discusses important considerations on pre-analytical, analytical and post-analytical aspects of PD-L1 IHC testing, including specimen type, validation of assays, external quality assurance and training.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Yokoi, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709937 · Cited by 4,593
Camp, R. L., Dolled-Filhart, M., & Rimm, D. L. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0713 · Cited by 3,744
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab plus chemotherapy for squamous non-small-cell lung cancer
Paz-Ares, L., Luft, A., Vicente, D., Tafreshi, A., Gümüş, M., Mazières, J., Hermes, B., Çay Şenler, F., Csőszi, T., Fülöp, A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1810865 · Cited by 3,617
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Mok, T. S. K., Wu, Y.-L., Kudaba, I., Kowalski, D. M., Cho, B. C., Turna, H. Z., Castro, G., Srimuninnimit, V., Laktionov, K. K., Bondarenko, I., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32409-7 · Cited by 3,303
Self-citationNivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
First-Line Nivolumab in Stage IV or Recurrent Non–Small-Cell Lung Cancer
Carbone, D. P., Reck, M., Paz-Ares, L., Creelan, B., Horn, L., Steins, M., Felip, E., van den Heuvel, M. M., Ciuleanu, T.-E., Badin, F., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613493 · Cited by 2,503
Reck, M., Rodríguez–Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.00149 · Cited by 1,670
West, H., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30167-6 · Cited by 1,662
Hirsch, F. R., McElhinny, A., Stanforth, D., Ranger-Moore, J., Jansson, M., Kulangara, K., Richardson, W., Towne, P., Hanks, D., Vennapusa, B., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.11.2228 · Cited by 1,270
Self-citationQuantitative Assessment of the Heterogeneity of PD-L1 Expression in Non–Small-Cell Lung Cancer
McLaughlin, J., Han, G., Schalper, K. A., Carvajal-Hausdorf, D., Pelekanou, V., Rehman, J., Velcheti, V., Herbst, R., LoRusso, P., & Rimm, D. L. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2015.3638 · Cited by 837
Tsao, M. S., Kerr, K. M., Kockx, M., Beasley, M.-B., Borczuk, A. C., Botling, J., Bubendorf, L., Chirieac, L., Chen, G., Chou, T.-Y., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.013 · Cited by 794
Self-citationRimm, D. L., Han, G., Taube, J. M., Yi, E. S., Bridge, J. A., Flieder, D. B., Homer, R., West, W. W., Wu, H., Roden, A. C., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.0013 · Cited by 764
Self-citationIlie, M., Long-Mira, E., Bence, C., Butori, C., Lassalle, S., Bouhlel, L., Fazzalari, L., Zahaf, K., Lalvée, S., Washetine, K., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdv489 · Cited by 587
Vokes, E. E., Ready, N., Felip, E., Horn, L., Burgio, M. A., Antonia, S. J., Arén Frontera, O., Gettinger, S., Holgado, E., Spigel, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy041 · Cited by 464
Harmonized PD-L1 immunohistochemistry for pulmonary squamous-cell and adenocarcinomas
Scheel, A. H., Dietel, M., Heukamp, L. C., Jöhrens, K., Kirchner, T., Reu, S., Rüschoff, J., Schildhaus, H.-U., Schirmacher, P., Tiemann, M., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.117 · Cited by 347
Mansfield, A. S., Aubry, M. C., Moser, J. C., Harrington, S. M., Dronca, R. S., Park, S. S., & Dong, H. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw289 · Cited by 336
Bass, B. P., Engel, K. B., Greytak, S. R., & Moore, H. M. (2014) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0691-ra · Cited by 316
Ratcliffe, M. J., Sharpe, A., Midha, A., Barker, C., Scott, M., Scorer, P., Al-Masri, H., Rebelatto, M. C., & Walker, J. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-2375 · Cited by 301
Calles, A., Liao, X., Sholl, L. M., Rodig, S. J., Freeman, G. J., Butaney, M., Lydon, C., Dahlberg, S. E., Hodi, F. S., Oxnard, G. R., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000687 · Cited by 271
Self-citationFehrenbacher, L., von Pawel, J., Park, K., Rittmeyer, A., Gandara, D. R., Ponce Aix, S., Han, J.-Y., Gadgeel, S. M., Hida, T., Cortinovis, D. L., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.039 · Cited by 260
Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer
Adam, J., Le Stang, N., Rouquette, I., Cazes, A., Badoual, C., Pinot-Roussel, H., Tixier, L., Danel, C., Damiola, F., Damotte, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy014 · Cited by 215
Heymann, J. J., Bulman, W. A., Swinarski, D., Pagan, C. A., Crapanzano, J. P., Haghighi, M., Fazlollahi, L., Stoopler, M. B., Sonett, J. R., Sacher, A. G., et al. (2017) · Cancer Cytopathology · doi:10.1002/cncy.21937 · Cited by 202
A Quantitative Comparison of Antibodies to Programmed Cell Death 1 Ligand 1
Gaule, P., Smithy, J. W., Toki, M., Rehman, J., Patell-Socha, F., Cougot, D., Collin, P., Morrill, P., Neumeister, V., & Rimm, D. L. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.3015 · Cited by 201
Brunnström, H., Johansson, A., Westbom-Fremer, S., Backman, M., Djureinovic, D., Patthey, A., Isaksson-Mettävainio, M., Gulyas, M., & Micke, P. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.59 · Cited by 200
Development of an automated PD-L1 immunohistochemistry (IHC) assay for non-small cell lung cancer
Phillips, T., Simmons, P., Inzunza, H. D., Cogswell, J., Novotny, J., Taylor, C., & Zhang, X. (2015) · Applied Immunohistochemistry & Molecular Morphology · doi:10.1097/pai.0000000000000256 · Cited by 189
Sheng, J., Fang, W., Yu, J., Chen, N., Zhan, J., Ma, Y., Yang, Y., Huang, Y., Zhao, H., & Zhang, L. (2016) · Scientific Reports · doi:10.1038/srep20090 · Cited by 188
Zhang, P., Ma, Y., Lv, C., Huang, M., Li, M., Dong, B., Liu, X., An, G., Zhang, W., Zhang, J., et al. (2016) · Cancer Science · doi:10.1111/cas.13072 · Cited by 184
Rebelatto, M. C., Midha, A., Mistry, A., Sabalos, C., Schechter, N., Li, X., Jin, X., Steele, K. E., Robbins, P. B., Blake-Haskins, J. A., et al. (2016) · Diagnostic Pathology · doi:10.1186/s13000-016-0545-8 · Cited by 179
Munari, E., Zamboni, G., Lunardi, G., Marchionni, L., Marconi, M., Sommaggio, M., Brunelli, M., Martignoni, G., Netto, G. J., Hoque, M. O., et al. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.04.017 · Cited by 170
Rehman, J. A., Han, G., Carvajal-Hausdorf, D. E., Wasserman, B. E., Pelekanou, V., Mani, N. L., McLaughlin, J., Schalper, K. A., & Rimm, D. L. (2017) · Modern Pathology · doi:10.1038/modpathol.2016.186 · Cited by 163
Comparison of Four PD-L1 Immunohistochemical Assays in Lung Cancer
Hendry, S. A., Byrne, D. J., Wright, G. M., Young, R. J., Sturrock, S., Cooper, W. A., & Fox, S. B. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.112 · Cited by 162
Self-citationDietel, M., Savelov, N., Salanova, R., Micke, P., Bigras, G., Hida, T., Antunez, J., Guldhammer Skov, B., Hutarew, G., Sua, L. F., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.06.012 · Cited by 158
Skov, B. G., & Skov, T. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000540 · Cited by 155
Compton, C. C., Robb, J. A., Anderson, M. W., Berry, A. B., Birdsong, G. G., Bloom, K. J., Branton, P. A., Crothers, J. W., Cushman‐Vokoun, A. M., Hicks, D. G., et al. (2019) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2019-0009-sa · Cited by 153
Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non–Small Cell Lung Cancer
Cooper, W. A., Russell, P. A., Cherian, M., Duhig, E., Godbolt, D., Jessup, P. J., Khoo, C., Leslie, C., Mahar, A. M., Moffat, D. F. C., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-0151 · Cited by 149
Self-citationSpigel, D. R., de Marinis, F., Giaccone, G., Reinmuth, N., Vergnenégre, A., Barrios, C. H., Morise, M., Felip, E., Andric, Z. G., Geater, S. L., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz293 · Cited by 146
Uruga, H., Bozkurtlar, E. B., Huynh, T. G., Muzikansky, A., Goto, Y., Gomez‐Caraballo, M., Hata, A. N., Gainor, J. F., Mark, E. J., Engelman, J. A., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.10.015 · Cited by 138
Self-citationNoll, B., Wang, W., Gong, Y., Zhao, J., Kalhor, N., Prieto, V. G., Staerkel, G., & Roy‐Chowdhuri, S. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21987 · Cited by 118
Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer
Wang, H., Agulnik, J. S., Kasymjanova, G., Wang, A., Jiménez, P. P., Cohen, V., Small, D. I., Pepe, C., Sakr, L., Fiset, P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy126 · Cited by 113
Marchetti, A., Barberis, M. C. P., Franco, R., Luca, G. D., Pace, M. V., Staibano, S., Volante, M., Buttitta, F., Guerini‐Rocco, E., Righi, L., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.07.031 · Cited by 106
Self-citationA Harmonization Study for the Use of 22C3 PD-L1 Immunohistochemical Staining on Ventana’s Platform
Neuman, T., London, M., Kania-Almog, J., Litvin, A., Zohar, Y., Fridel, L., Sandbank, J., Barshak, I., & Vainer, G. W. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.08.146 · Cited by 97
Russell-Goldman, E. E., Kravets, S., Dahlberg, S. E., Sholl, L. M., & Vivero, M. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21973 · Cited by 95
Self-citationRizvi, N. A., Cho, B. C. C., Reinmuth, N., Lee, K. H., Ahn, M., Luft, A. V., van den Heuvel, M. M., Cobo, M., Smolin, A., Vicente, D., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy511.005 · Cited by 92
Ilié, M., Juco, J. W., Huang, L., Hofman, V., Khambata‐Ford, S., & Hofman, P. M. (2018) · Cancer Cytopathology · doi:10.1002/cncy.21977 · Cited by 89
Munari, E., Rossi, G., Zamboni, G., Lunardi, G., Marconi, M., Sommaggio, M., Netto, G. J., Hoque, M. O., Brunelli, M., Martignoni, G., et al. (2018) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001105 · Cited by 88
PD ‐L1 testing for lung cancer in the UK : recognizing the challenges for implementation
Cree, I. A., Booton, R., Cane, P., Gosney, J. R., Ibrahim, M., Kerr, K. M., Lal, R., Lewanski, C. R., Navani, N., Nicholson, A. G., et al. (2016) · Histopathology · doi:10.1111/his.12996 · Cited by 85
Self-citationO’Malley, D. P., Yang, Y., Boisot, S., Sudarsanam, S., Wang, J., Chizhevsky, V., Zhao, G., Arain, S., & Weiss, L. M. (2019) · Modern Pathology · doi:10.1038/s41379-019-0210-3 · Cited by 85
Evans, M., O’Sullivan, B., Hughes, F., Mullis, T., Smith, M. R., Trim, N., & Tanière, P. (2018) · Pathology & Oncology Research · doi:10.1007/s12253-018-0469-6 · Cited by 82
Thunnissen, E., Allen, T. C., Adam, J., Aisner, D. L., Beasley, M. B., Borczuk, A., Cagle, P. T., Capelozzi, V. L., Cooper, W. A., Hariri, L. P., et al. (2017) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2017-0106-sa · Cited by 80
Self-citationwritten on behalf of AME Lung Cancer Collaborative Group, Li, H., Xu, Y., Wan, B., Song, Y., Zhan, P., Hu, Y., Zhang, Q., Zhang, F., Liu, H., et al. (2019) · Translational Lung Cancer Research · doi:10.21037/tlcr.2019.08.04 · Cited by 79
Self-citationGagné, A., Wang, E., Bastien, N., Orain, M., Desmeules, P., Pagé, S., Trahan, S., Couture, C., Joubert, D., & Joubert, P. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.2503 · Cited by 71
Torous, V. F., Rangachari, D., Gallant, B. P., Shea, M., Costa, D. B., & VanderLaan, P. A. (2018) · Journal of the American Society of Cytopathology · doi:10.1016/j.jasc.2018.02.003 · Cited by 64
Liu, Y., Dong, Z., Jiang, T., Hou, L., Wu, F., Gao, G., He, Y., Zhao, J., Li, X., Zhao, C., et al. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.02.008 · Cited by 64
Self-citationFujimoto, D., Sato, Y., Uehara, K., Ishida, K., Fukuoka, J., Morimoto, T., Kawachi, H., Mori, R., Ito, M., Teraoka, S., et al. (2017) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2017.11.123 · Cited by 62
Munari, E., Zamboni, G., Sighele, G., Marconi, M., Sommaggio, M., Lunardi, G., Rossi, G., Cavazza, A., Moretta, F., Gilioli, E., et al. (2018) · Cancer Cytopathology · doi:10.1002/cncy.22083 · Cited by 57
Boothman, A.-M., Scott, M. L. J., Ratcliffe, M., Whiteley, J. L., Dennis, P. A., Wadsworth, C., Sharpe, A. D., Rizvi, N. A., Garassino, M. C., & Walker, J. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.04.025 · Cited by 56
Horn, L., Gettinger, S. N., Gordon, M. S., Herbst, R. S., Gandhi, L., Felip, E., Sequist, L. V. D., Spigel, D. R., Antonia, S. J., Balmanoukian, A. S., et al. (2018) · European Journal of Cancer · doi:10.1016/j.ejca.2018.06.031 · Cited by 55
Giunchi, F., Degiovanni, A., Daddi, N., Trisolini, R., Dell’Amore, A., Agostinelli, C., Ardizzoni, A., & Fiorentino, M. (2016) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000458 · Cited by 53
Kim, H., Kwon, H. J., Park, S. Y., Park, E., & Chung, J.-H. (2017) · Oncotarget · doi:10.18632/oncotarget.21567 · Cited by 52
Self-citationKerr, K. M., Thunnissen, E., Dafni, U. G., Finn, S. P., Bubendorf, L., Soltermann, A., Verbeken, E. K., Biernat, W., Warth, A., Marchetti, A., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.012 · Cited by 52
Self-citationLozano, M. D., Abengozar‐Muela, M., Echeveste, J. I., Subtil, J., Bertó, J., Gúrpide, A., Calvo, A., & de Andrea, C. E. (2019) · Cancer Cytopathology · doi:10.1002/cncy.22155 · Cited by 47
Immunohistochemistry should undergo robust validation equivalent to that of molecular diagnostics
Elliott, K., McQuaid, S., Salto‐Tellez, M., & Maxwell, P. (2015) · Journal of Clinical Pathology · doi:10.1136/jclinpath-2015-203178 · Cited by 45
Lloyd, I. E., Zhou, W., Witt, B. L., & Chadwick, B. E. (2017) · Applied immunohistochemistry & molecular morphology · doi:10.1097/pai.0000000000000572 · Cited by 39
Munari, E., Zamboni, G., Lunardi, G., Marconi, M., Sommaggio, M., Brunelli, M., Martignoni, G., Netto, G. J., Hoque, M. O., Moretta, F., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.25770 · Cited by 34
Omori, S., Kenmotsu, H., Abe, M., Watanabe, R., Sugino, T., Kobayashi, H., Nakashima, K., Wakuda, K., Ono, A., Taira, T., et al. (2018) · International Journal of Clinical Oncology · doi:10.1007/s10147-018-1305-4 · Cited by 33
Naito, T., Udagawa, H., Sato, J., Horinouchi, H., Murakami, S., Goto, Y., Kanda, S., Fujiwara, Y., Yamamoto, N., Zenke, Y., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.019 · Cited by 31
Self-citationComparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263
Fujimoto, D., Yamashita, D., Fukuoka, J., Kitamura, Y., Hosoya, K., Kawachi, H., Sato, Y., Nagata, K., NAKAGAWA, A., Tachikawa, R., et al. (2018) · Anticancer Research · doi:10.21873/anticanres.13065 · Cited by 30
Kim, J., Cho, J., Lee, M. H., & Lim, J. H. (2018) · Scientific Reports · doi:10.1038/s41598-018-30277-0 · Cited by 29
Impact of delayed fixation and decalcification on PD-L1 expression: a comparison of two clones
Forest, F., Cote, G., Laville, D., Cruz, V. D., Col, P. D., Camy, F., Mobarki, M., Clémenson, A., Yvorel, V., & Péoc’h, M. (2019) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-019-02613-w · Cited by 26
Reliability of PD-L1 assays using small tissue samples compared with surgical specimens
Kim, I., Kim, A., Lee, C. H., Lee, G., Kim, A., Jo, E. J., Kim, M., Mok, J., Lee, K., Kim, K. U., et al. (2019) · Medicine · doi:10.1097/md.0000000000014972 · Cited by 23
Conde, E., Caminoa, A., Domínguez, C., Calles, A., Walter, S., Angulo, B., Sánchez, E., Alonso, M., Jimenez, L., Madrigal, L. Í., et al. (2017) · Histopathology · doi:10.1111/his.13346 · Cited by 21
Validation of immunocytochemistry as a morphomolecular technique
Maxwell, P., & Salto‐Tellez, M. (2016) · Cancer Cytopathology · doi:10.1002/cncy.21692 · Cited by 20
Jotte, R. M., Cappuzzo, F., Vynnychenko, I. O., Stroyakovskiy, D., Rodríguez‐Abreu, D., Hussein, M., Soo, R. A., Conter, H. J., Kozuki, T., Huang, K., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.484 · Cited by 20
Effects of Decalcifying Agents of Variable Duration on PD-L1 Immunohistochemistry
Strickland, A. L., Blacketer, S., Molberg, K. H., Markantonis, J., & Lucas, E. (2019) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz161 · Cited by 16
Adam, J., Hofman, V., Mansuet‐Lupo, A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.08.1666 · Cited by 12
Cited by
PD-L1 as a biomarker of response to immune-checkpoint inhibitors
Doroshow, D. B., Bhalla, S., Beasley, M. B., Sholl, L. M., Kerr, K. M., Gnjatic, S., Wistuba, I. I., Rimm, D. L., Tsao, M. S., & Hirsch, F. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00473-5 · Cited by 1,575
Self-citationThe 2021 WHO Classification of Lung Tumors: Impact of Advances Since 2015
Nicholson, A. G., Tsao, M. S., Beasley, M. B., Borczuk, A. C., Brambilla, E., Cooper, W. A., Dacic, S., Jain, D., Kerr, K. M., Lantuejoul, S., et al. (2022) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2021.11.003 · Cited by 1,554
Self-citationHendriks, L. E., Kerr, K. M., Menis, J., Mok, T. S., Nestle, U., Passaro, A., Peters, S., Planchard, D., Smit, E. F., Solomon, B. J., et al. (2023) · Annals of Oncology · doi:10.1016/j.annonc.2022.12.013 · Cited by 620
Self-citationImyanitov, E. N., Iyevleva, A. G., & Levchenko, E. V. (2021) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103194 · Cited by 526
Sholl, L. M., Hirsch, F. R., Hwang, D., Botling, J., Lopez-Rios, F., Bubendorf, L., Mino-Kenudson, M., Roden, A. C., Beasley, M. B., Borczuk, A., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.05.019 · Cited by 283
Self-citation
Metadata
- Authors
- Lantuejoul, S., Sound-Tsao, M., Cooper, W. A., Girard, N., Hirsch, F. R., Roden, A. C., Lopez-Rios, F., Jain, D., Chou, T.-Y., Motoi, N., Kerr, K. M., Yatabe, Y., Brambilla, E., Longshore, J., Papotti, M., Sholl, L. M., Thunnissen, E., Rekhtman, N., Borczuk, A., Bubendorf, L., Minami, Y., Beasley, M. B., Botling, J., Chen, G., Chung, J.-H., Dacic, S., Hwang, D., Lin, D., Moreira, A., Nicholson, A. G., Noguchi, M., Pelosi, G., Poleri, C., Travis, W., Yoshida, A., Daigneault, J. B., Wistuba, I. I., & Mino-Kenudson, M.
- Venue
- Journal of Thoracic Oncology
- Publisher
- Elsevier BV
- Published
- 2020-04
- Volume
- 15
- Issue
- 4
- Pages
- 499-519
- ISSN
- 1556-0864 (ISSN-L)
- OpenAlex
- W2995123342
- Cited by
- 332
- References
- 85
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.